PharmaShots | Incisive News in 3 Shots

Subscribe Now

Severe Allergic Asthma

Novartis' Xolair (omalizumab) Receives EU's Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

Novartis' Xolair (omalizumab) Receives EU's Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

December 14, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us